GlassScriptPhysician profile
Larissa Elgudin
NPI 1629004387
$5,506.90
in general payments reported to CMS, 2019-2025
25 companies · $812 in 2025
The $812 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $29.20 · 2021: $1,089 · 2022: $791 · 2023: $1,501 · 2024: $879 · 2025: $812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,143 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,143.31 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $795.03 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $663.21 | 2019-2025 | Rexulti |
| Abbvie INC. | $590.56 | 2021-2025 | |
| Axsome Therapeutics, INC. | $482.34 | 2023-2025 | Auvelity |
| Abbott Laboratories | $429.42 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $360.46 | 2023-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $357.11 | 2021-2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $334.18 | 2019-2024 | Trintellix |
| Alkermes, INC. | $310.34 | 2022-2025 | Lybalvi, Aristada |
| Neos Therapeutics, LP | $185.91 | 2021-2025 | Adzenys Xr-Odt |
| Corium, LLC | $157.37 | 2023-2025 | Azstarys, Azstarys |
| Vanda Pharmaceuticals INC. | $149.61 | 2019-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $131.60 | 2019-2025 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $115.53 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $108.49 | 2021-2025 | Qelbree |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $85.55 | 2023-2025 | Austedo Xr, Austedo Xr |
| Tris Pharma INC | $82.92 | 2022-2025 | Dyanavel Xr |
| Bausch Health US, LLC | $39.36 | 2021-2022 | |
| Shire North American Group INC | $31.15 | 2019 | |
| Ironshore Pharmaceuticals INC. | $23.60 | 2019 | |
| Alfasigma USA, INC. | $17.22 | 2021 | |
| Collegium Pharmaceutical, INC. | $15.12 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $15.04 | 2019 | |
| Jazz Pharmaceuticals INC. | $13.88 | 2021 | |
| Neuronetics, INC. | $11.90 | 2023 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larissa Elgudin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.